ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer

Running, not enrolling · Phase 1

Conditions studied: Metastatic Prostate Cancer

In brief

This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate cancer (mPC).

Key facts

Study ID

NCT04662580

Run by

Janssen Research & Development, LLC

People needed

183

Starts

2021-05-03

Expected to finish

2026-12-31

Last updated by the study team

2026-07-06

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• UC San Diego Moores Cancer Center — La Jolla, California, United States
• University of California, Los Angeles School of Medicine — Los Angeles, California, United States
• UCSF Medical Center at Mission Bay — San Francisco, California, United States
• Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
• Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana, United States
• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• Washington University St. Louis School Medicine Siteman Cancer Center — St Louis, Missouri, United States
• GU Research Network — Omaha, Nebraska, United States
• Weill Cornell Medical College — New York, New York, United States
• University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States
• Carolina Urologic Research Center — Myrtle Beach, South Carolina, United States
• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.